Rapamycin (Sirolimus)

Pfizer辉瑞授权 目录号:S1039 别名: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus)是一种特定的 mTOR 抑制剂,在 HEK293细胞中,IC50 为 ~0.1 nM。

规格 价格 库存 购买数量  
RMB 2501.99 现货
RMB 580.39 现货
RMB 2216.87 现货
RMB 5501.68 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献64篇:

客户使用该产品的13个实验数据:

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Cells were cultured with the indicated concentrations of PLS-123, rapamycin (Granta519 0.002 μM, Mino 0.001 μM, Z138 0.005 μM), and their combination for 48 h. The results are expressed as the mean of relative activity and S.D. from triplicate cultures. The results are representative of at least three similar experiments.

    Int J Cancer, 2018, 142(1):202-213. Rapamycin (Sirolimus) purchased from Selleck.

  • Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

    Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

    Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

  • Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

产品安全说明书

mTOR抑制剂选择性比较

生物活性

产品描述 Rapamycin (Sirolimus)是一种特定的 mTOR 抑制剂,在 HEK293细胞中,IC50 为 ~0.1 nM。
靶点
mTOR [1]
(HEK293 cells)
~0.1 nM
体外研究

Rapamycin作用于HEK293细胞,抑制内源性mTOR活性,IC50为~0.1 nM,而iRap和AP21967 作用时,IC50分别为~5 nM 和~10 nM。[1] Rapamycin处理酿酒酵母,诱导细胞周期停在G1/S期,且抑制翻译。[2] Rapamycin显著抑制T98G和U87-MG细胞活力,这种作用具有剂量依赖性,IC50分别为2 nM和 1 μM, 而对U373-MG细胞没有作用活性,IC50>25 μM。Rapamycin(100 nM) 作用于对Rapamycin敏感的U87-MG和T98G细胞,通过抑制mTOR功能,而诱导细胞周期停在G1期,也诱导自噬而不是凋亡。[6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 M{LiTGN6fG:2b4jpZ{BCe3OjeR?= MYWxNEBvVQ>? NIflXnI4OiCq MXfEUXNQ MYHQc5RmdnSrYYTld{Bk[W2ydH;0bIVkcW5vaX7keYNm\CCleYTveI95cWOrdIm= NGrFZ3gzPDlyMEi3Ny=>
HT-29 MUjDfZRwfG:6aXOgRZN{[Xl? Ml\1NVAhdk1? MWW3NkBp M1vhXGROW09? NH\6TIlRd3SnboTpZZRmeyCmaXfpeI95cW5vaX7keYNm\CCleYTveI95cWOrdIm= MV:yOFkxODh5Mx?=
HT-29 NIHjTpdEgXSxdH;4bYMhSXO|YYm= NF;2fHMyOCCwTR?= MoXIO|IhcA>? M{HZ[GROW09? NE[ze|JRd3SnboTpZZRmeyB3LX\seY9zd3W{YXPpcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? NE\5OmMzPDlyMEi3Ny=>
PC3 NHPTO5VMcW6jc3WgRZN{[Xl? MXOxNFAhdk1? NVnBVI5jOSCq NV75WotvTE2VTx?= NV[yfm57WG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDxzMDDuUU4> MYiyNVk4QDZ6Mx?=
PC3 MVnLbY5ie2ViQYPzZZk> MmnCNVAxKG6P MWWxJIg> MWfEUXNQ NEexW4tFd2W|IH7veEBqdmirYnn0JI1VV1JvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?= M2LLflIyQTd6Nkiz
PC3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHBNU42KM7:TR?= M3[0WlEhcA>? M1\FSWROW09? NV3pdohCUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczD3bZRpKEmFNUCgc4YhRDFyIH7N NFLXXZMzOTl5OE[4Ny=>
HEK293 M1TEbGZ2dmO2aX;uJGF{e2G7 MoLpNVAxKG6P NHPndmg5KGh? MlHMSG1UVw>? NYG3NlVSUW6qaXLpeJMhXFCDLXnu[JVk\WRiZHXndoFl[XSrb36gc4YhWGSlZESge4l1cCCHQ{WwJI9nKDVyIH7N MUOyNVU{QTNyMR?=
BT-20 M4DLZWtqdmG|ZTDBd5NigQ>? M{nJPVIxKM7:TR?= MnO0SG1UVw>? NIfhblVFd2W|IH7veEBqdmirYnn0JI1VV1KFMjDk[ZBmdmSnboSgdGFsXCCVNEezJJBpd3OyaH;yfYxifGmxbh?= MlzDNlE{PTN3NUG=
U937 NYr2PVZXSW62aXLhZ5RmemmjbDDBd5NigQ>? MmjzOVAh|ryP MorWOFghcA>? MojVSG1UVw>? MYPJcoR2[2W|IHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhVGWpaX;u[Yxt[SCybnX1cY9xcGmuYTDQbIlt[WSnbIDobYEuOSCMUkOyJIlvKFV7M{egZ4VtdHN? MXqyNVE1OjFyNh?=
U937 NW\HeHhISW62aXLhZ5RmemmjbDDBd5NigQ>? MljROVAh|ryP NY\hdYFNPDhiaB?= NHjLT|NFVVOR NV3pN4FsTG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCPSWCgdJJwfGWrbj3k[YZq[2mnboSgUIVocW:wZXzsZUBxdmW3bX;wbIlt[SCMUkOyMVIhcW5iVUmzO{Bk\Wyucx?= NFfHcWozOTF2MkGwOi=>
U937 M4XlU2FvfGmkYXP0[ZJq[WxiQYPzZZk> MkjsOVAh|ryP Ml\wOFghcA>? NFjwZ2hFVVOR M4TTXmRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhTXOlaHXybYNpcWFiY3;sbUBJSjFyMTDpckBWQTN5IHPlcIx{ NHTVZZozOTF2MkGwOi=>
MCF-7 NVf5cGZSSXW2b4DoZYd6KEG|c3H5 MX[zNEBvVQ>? MUi0JIg> MVTEUXNQ M33NNWlv\HWlZYOgZZV1d3CqYXf5 MlvINlAxOjhzM{S=
U87MG M4W2[WtqdmG|ZTDBd5NigQ>? M4DDPFEh|ryP NUfjXWNPPiCq MWXEUXNQ NW\CdGIzWG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36= MUKxPVg1QDRyNB?=
U87MG MkjFT4lv[XOnIFHzd4F6 M{TXOlEh|ryP M{XFelYhcA>? NXq0RYhvTE2VTx?= NGPNV3FRd3SnboTsfUBqdmirYnn0d{A1TUKSMTjUO|AqKHCqb4PwbI9zgWyjdHnvci=> NH6xXWUyQTh2OESwOC=>
U87MG MYPLbY5ie2ViQYPzZZk> MYmxJO69VQ>? MUm2JIg> NVqxTmtOTE2VTx?= M2D4PWRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w M4DFOFE6QDR6NEC0
U87MG MnWxT4lv[XOnIFHzd4F6 M1X6N|Eh|ryP NHrRVGg3KGh? NFG3OmlFVVOR NIHQWYJFd2W|IH7veEBqdmirYnn0JHAuPEWEUEGoWFM4NzR4KTDwbI9{eGixconsZZRqd25? NHT4[YcyQTh2OESwOC=>
COS7 cells expressing EGFP-HDQ74/rheb NX7Y[Vl5SXW2b4DoZYd6KEG|c3H5 MUGwMlIh|ryP NGfOdmczPCCq NEHMfJVFVVOR NF3telhKdmS3Y3XzJIF2fG:yaHHnfS=> MoT0NVg{QTF7NEm=
COS7 cells expressing EGFP-LC3 M2fkOWF2fG:yaHHnfUBCe3OjeR?= NYPGTVB2OC5{IN88US=> MoD3NlQhcA>? M1zYVGROW09? M3fkNmlv\HWlZYOgZZV1d3CqYXf5 MV2xPFM6OTl2OR?=
H4 MYjGeY5kfGmxbjDBd5NigQ>? MoS0NE4zKM7:TR?= M1rZW|I1KGh? M2W4NWROW09? M2jhWmlv[3KnYYPld{B1cGVicnH0bY8hd2ZibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFIhfG9ibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFEhcW5iaIXtZY4hUDRiY3XscJM> NGXRXZAyQDB{NEW4OC=>
HeLa NFvWRnFHfW6ldHnvckBCe3OjeR?= Mn7ONVAxKG6P MXyzOkBp M2iwNGROW09? NIT4SWZKdmS3Y3XzJGZTSiCNMkC5OXAtKFR{MEm4UEwhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v MVKxO|U3OzN6NR?=
HeLa NXzpRYhtTnWwY4Tpc44hSXO|YYm= NVXGeXlnOTByIH7N NIjofZI{PiCq M3W3eWROW09? MlLGTY5lfWOnczDGVmIhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v MUCxO|U3OzN6NR?=
HeLa MYXGeY5kfGmxbjDBd5NigQ>? NVK2VVRROTByIH7N MXizOkBp NUL0[XVITE2VTx?= NF[5cYJKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> NFL2TWcyPzV4M{O4OS=>
SYF NF\yZ2VHfW6ldHnvckBCe3OjeR?= M2LFSVExOCCwTR?= NWjmcndnOjRiaB?= NEnrXIVFVVOR NUTDSXk4UW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v MX2xO|U3OzN6NR?=
SYF Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7CNo9NOTByIH7N MmXSNlQhcA>? MULEUXNQ MVrJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiU2nGJINmdGy| MXexO|U3OzN6NR?=
HEK293T NX3Tb5hISW62aY\pdoFtKEG|c3H5 M2eyWVEhdk1? NH2ye3Y1KGR? MUDEUXNQ MlXXTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFJ3IIfpeIghTUN3MDDv[kAxNjFibl2= NX35[mpMOTd2OEW1NFE>
HEK293T MWLBcpRqfmm{YXygRZN{[Xl? NEfGUpkyKG6P MYm0JIQ> MlTZSG1UVw>? Ml3RTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFh2IIfpeIghTUN3MDDv[kAxNjNibl2= NIXOcWIyPzR6NUWwNS=>
PBMC NGDuenFHfW6ldHnvckBCe3OjeR?= MYGxJI5O Mk\WNVQh\A>? MYXEUXNQ Mn62VoVlfWOnczDDR3I2KGSnboPpeJk> M2jzTFE4PDh3NUCx
PBMC MXvGeY5kfGmxbjDBd5NigQ>? NWf1SnZ1OSCwTR?= NX\CSIxwOTRiZB?= Ml;iSG1UVw>? MoLISI9meyCwb4SgZYZn\WO2IFPYR3I1KGSnboPpeJk> M2rzNlE4PDh3NUCx
HEK293 cells NGGzVFBMcW6jc3WgRZN{[Xl? MlPjOVAhdk1? MXK0OUBucW5? NUnhT48zTE2VTx?= NWfGPWJUUW6qaXLpeJMhdVSRUjDrbY5ie2ViYXP0bZZqfHlid3n0bEBKSzVyIH;mJFAvOSCwTR?= NVzJeGFCOTd|NUC5OVM>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NXjUbIFqTnWwY4Tpc44hSXO|YYm= NYDwcpdHOTByIH7N M{Lw[FQhcA>? MXjEUXNQ NHuyRoZKdmS3Y3XzJIx2[2moZYLhd4UheHKxdHXpckB1emGwcz3zdIxq[2mwZzDpckBFem:|b4DobYxiKG2nbHHuc4die3SncjDTNkBk\WyuczD0doFve2[nY4Tl[EB4cXSqIF6tcJVkKGGwZDDDMYx2[w>? NFjIZnAyPzF{OEK2Ni=>
Human mixed lymphocyte M{DKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HtVFUhdk1? NVfLdlI4TE2VTx?= NVra[JJ3UUN3ME2xMlYhdk1w M1XjZVE3OTh3OE[1
Lewis rat lymph node cells MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f5OVUh|ryP NX25THJFTE2VTx?= MXzJR|UxRTJwNjFOwG0> M3SxPVE3OTh3OE[1
cells from the thymus of normal BALB/c mice NEDSRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnL2NVAhdk1? MXy3NkBp NYO1XJRMTE2VTx?= MYXJcohq[mm2czDsfY1xcG:ycn;sbYZmemG2aX;uJEhNSUZrIIfpeIghUUN3MDDv[kA{KG6P MXSxNFAzOTl2OB?=
MRK-nu-1 NVPnbplvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\FT3VKSzVyPUCuPFQ2KHCP MorCV2FPT0WU
OCUB-M MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;pTWM2OD13LkK0JJBO MnPBV2FPT0WU
SF539 M3nxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFzLk[gdG0> M{L5PHNCVkeHUh?=
ES4 MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;rTWM2OD1{MT61JJBO MkPCV2FPT0WU
RL95-2 NFPuRlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHBTWM2OD1zMEegdG0> NIXzRohUSU6JRWK=
LC-2-ad NH;kUHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFj1VnRKSzVyPUSyN{BxVQ>? M1fPbHNCVkeHUh?=
Daudi MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvTTWM2OD12M{SgdG0> NYDZd5pmW0GQR1XS
NTERA-S-cl-D1 M1nhWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfxXmRmUUN3ME20OFMheE1? NFnLRWZUSU6JRWK=
OS-RC-2 NHPSTFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTZ3MjDwUS=> NEHlXXRUSU6JRWK=
VA-ES-BJ MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\ZTWM2OD15MkOgdG0> MWrTRW5ITVJ?
GR-ST MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTh2NjDwUS=> Ml3wV2FPT0WU
SW872 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4W3dWlEPTB;OES2JJBO M4H4U3NCVkeHUh?=
NOS-1 M3XIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGX1RVBKSzVyPUi3NUBxVQ>? Mn7nV2FPT0WU
MC116 NFHFV|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rIbGlEPTB;OUi1JJBO MWXTRW5ITVJ?
NCI-H1355 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjme|dKSzVyPUGuNFEhdk1? NV[wNmN6W0GQR1XS
RPMI-8226 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fjb2lEPTB;MT6xPUBvVQ>? MmrIV2FPT0WU
TE-15 NUTkW3hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFwM{[gcm0> MVPTRW5ITVJ?
Ramos-2G6-4C10 NHna[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rDWWlEPTB;MT60OkBvVQ>? M4nweXNCVkeHUh?=
KU812 NUK1ToxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJwMEGgcm0> Mmf6V2FPT0WU
EW-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmm0TWM2OD1{LkG3JI5O M17jenNCVkeHUh?=
KS-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PsTWlEPTB;Mj60OUBvVQ>? MV;TRW5ITVJ?
SK-LMS-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJwNEmgcm0> MnraV2FPT0WU
TGBC1TKB M13EVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJwNkmgcm0> NYK3SZFXW0GQR1XS
TE-6 M3f3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3kTVFkUUN3ME2yMlc4KG6P MUHTRW5ITVJ?
ETK-1 NFe0XG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJwOEKgcm0> NYfTboZLW0GQR1XS
BE-13 M1rTPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJwOUmgcm0> M4P3XHNCVkeHUh?=
A3-KAW MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJwOUmgcm0> MnrOV2FPT0WU
TE-10 NXHL[ldJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XtdGlEPTB;Mz6zJI5O M1TORXNCVkeHUh?=
DOHH-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIe2coJKSzVyPUOuN|Uhdk1? MmXsV2FPT0WU
ES6 M1[4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXKyfI86UUN3ME2zMlQ{KG6P MUTTRW5ITVJ?
OPM-2 NUTzRpQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTRwMUWgcm0> M2\2fHNCVkeHUh?=
SH-4 NXixU3BST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPrTWM2OD12LkO0JI5O NXX5VZp4W0GQR1XS
NB13 NVLjbVJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUi2bIZZUUN3ME20MlM3KG6P NVn6SlNXW0GQR1XS
HUTU-80 M1\2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTRwNEKgcm0> M2[3OXNCVkeHUh?=
CCRF-CEM NWCw[3ZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonNTWM2OD12Lkm0JI5O MkHrV2FPT0WU
TGBC24TKB MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHq[XRSUUN3ME21MlUyKG6P M2H6enNCVkeHUh?=
697 M4npXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XkbmlEPTB;Nj6yPEBvVQ>? NVvMSpNMW0GQR1XS
J-RT3-T3-5 NGG5cYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTZwNE[gcm0> NWPnWZk3W0GQR1XS
KALS-1 MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnEcZpXUUN3ME22MlU3KG6P NULMT2xCW0GQR1XS
no-10 M1nnOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\aRWlEPTB;Nz6yPUBvVQ>? M3XOTHNCVkeHUh?=
SK-NEP-1 NF23b2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRThwN{mgcm0> NWnNXHNEW0GQR1XS
L-540 MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTFyLkSyJI5O NWjtTnN2W0GQR1XS
JiyoyeP-2003 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX32bIIyUUN3ME2xNE46PCCwTR?= MlLHV2FPT0WU
HH MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX5cFJKSzVyPUGxMlM6KG6P NH31[IZUSU6JRWK=
SR NHSzTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\CTWM2OD1zMT60OUBvVQ>? NV2xSHF6W0GQR1XS
QIMR-WIL M4S5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTFzLki1JI5O MnHpV2FPT0WU
A4-Fuk MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTLS3Z6UUN3ME2xN{4yOiCwTR?= M2S5SnNCVkeHUh?=
CESS Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fufGlEPTB;MUOuNVMhdk1? MU\TRW5ITVJ?
KE-37 NELVb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjITWM2OD1zNj6wO{BvVQ>? M{fTd3NCVkeHUh?=
SK-UT-1 MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHlRnZKSzVyPUG2MlgyKG6P MUHTRW5ITVJ?
SIG-M5 MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLBXYZKSzVyPUG3MlI2KG6P M4XxRXNCVkeHUh?=
HT MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\ENFNKSzVyPUG3MlYhdk1? NGnNRZRUSU6JRWK=
DEL NF36SY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DlemlEPTB;MUeuPVkhdk1? NGnhenBUSU6JRWK=
SK-PN-DW M3SwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jEOGlEPTB;MkCuNlMhdk1? Mnf6V2FPT0WU
RPMI-8402 MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDvTWM2OD1{MT63O{BvVQ>? MVLTRW5ITVJ?
RPMI-6666 NWexfYVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nOV2lEPTB;MkSuOFIhdk1? NULySIRDW0GQR1XS
NCI-H720 NWm2RZAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3ITWM2OD1{NT60NUBvVQ>? Ml3XV2FPT0WU
EW-16 M3XZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTzWJpIUUN3ME2yOk45PyCwTR?= NX7UNo9YW0GQR1XS
BL-70 M4CyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTJ6LkO4JI5O NYPrT45{W0GQR1XS
SF126 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTNyLkO4JI5O NFjVZ4FUSU6JRWK=
BC-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vnNGlEPTB;M{GuNlYhdk1? NHjBWmxUSU6JRWK=
MHH-PREB-1 Ml\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInmd49KSzVyPUOyMlQ1KG6P MWjTRW5ITVJ?
A101D MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\pOWlEPTB;M{KuOlIhdk1? M3ri[HNCVkeHUh?=
NMC-G1 NIC2d5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTDTWM2OD1|Mz62O{BvVQ>? Ml6yV2FPT0WU
LB1047-RCC NVnBT4xwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGK4XYJKSzVyPUO0MlY6KG6P NEjCVpRUSU6JRWK=
EM-2 NWXvWo1{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDqSWFKSzVyPUO4MlU{KG6P NW\yWoN3W0GQR1XS
COLO-684 NIHQSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPtW5hHUUN3ME2zPU45KG6P MWLTRW5ITVJ?
Becker M4L5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPj[GtVUUN3ME20NU4xPSCwTR?= NVrYR4h5W0GQR1XS
BL-41 M4f2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4r5SGlEPTB;NEOuOlYhdk1? MofxV2FPT0WU
MDA-MB-134-VI NHTvPJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfGTWM2OD12ND6wNkBvVQ>? Mnz4V2FPT0WU
L-363 MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYq5fIp3UUN3ME20OE44OyCwTR?= MkTxV2FPT0WU
ECC4 NV:4epZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LNZ2lEPTB;NESuO|ghdk1? MkOxV2FPT0WU
A388 NGnoW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTR2LkiyJI5O NGrRUnRUSU6JRWK=
HEL NX3h[I9wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3IVGRKSzVyPUS5Mlc6KG6P MYnTRW5ITVJ?
RKO MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHtPXpKSzVyPUWwMlI6KG6P NHLWWZdUSU6JRWK=
KINGS-1 M1njS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTVzLkW1JI5O NWPofFhVW0GQR1XS
EB-3 M3e3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\VTWM2OD13Mj62O{BvVQ>? M{H2U3NCVkeHUh?=
ARH-77 M{\JVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTzTWM2OD13Mj64JI5O Mn\5V2FPT0WU
GCIY MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Pwb2lEPTB;NUOuOFYhdk1? MonZV2FPT0WU
NCI-H1304 NFfxbmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVG2VXhNUUN3ME21O{4zOiCwTR?= M{SyNnNCVkeHUh?=
KARPAS-299 NE\ZPJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjNeFlVUUN3ME22NU45OiCwTR?= M3OzeXNCVkeHUh?=
IA-LM M{HY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nZVGlEPTB;NkiuNVMhdk1? MV;TRW5ITVJ?
GI-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO2TWM2OD15MD6zPUBvVQ>? MleyV2FPT0WU
TE-11 MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWL6TINkUUN3ME23O{4yPyCwTR?= MkGzV2FPT0WU
LS-411N NHTIS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP4O|RKSzVyPUe3MlU4KG6P MnPzV2FPT0WU
no-11 MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2C0cWlEPTB;OEOuNlQhdk1? MmrJV2FPT0WU
MV-4-11 M3zPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jk[GlEPTB;OEOuO|Mhdk1? M37zenNCVkeHUh?=
BV-173 MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoKwTWM2OD16Mz65O{BvVQ>? MoT6V2FPT0WU
CMK MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIq2SJBKSzVyPUi0MlE3KG6P NIPxSYhUSU6JRWK=
LC4-1 NWXJ[Ig4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{CwRWlEPTB;OE[uO|Ihdk1? NYfxR4hjW0GQR1XS
COR-L279 Mmn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r5VmlEPTB;OEeuNlUhdk1? M2[3bHNCVkeHUh?=
NCI-H209 MnPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Ljc2lEPTB;OEeuOFEhdk1? NGSzZpJUSU6JRWK=
Raji M2jzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTh7LkeyJI5O M1:zUXNCVkeHUh?=
LB996-RCC NELSb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXPNGtKSzVyPUmzMlQ{KG6P NEPZbJhUSU6JRWK=
NCI-H526 M4XnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLhTWM2OD17Mz61PUBvVQ>? NF3XcJVUSU6JRWK=
KGN NXW3VYZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M174SWlEPTB;OU[uNlkhdk1? M1HD[nNCVkeHUh?=
MOLT-4 NGjobWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTl4Lke5JI5O NFTrWItUSU6JRWK=
PF-382 M1\2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3VWJFKSzVyPUm2Mlc6KG6P MoPGV2FPT0WU
BC-3 M{Tj[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PqW2lEPTB;OUmuNVghdk1? NHjuXZVUSU6JRWK=
KARPAS-422 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTFyMj6wPUBvVQ>? MUfTRW5ITVJ?
SBC-1 NYn6XGV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHBTWM2OD1zMEeuO|Uhdk1? NHjGN41USU6JRWK=
LC-1F NH7Td4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTFyOD6wOUBvVQ>? NGqwZW9USU6JRWK=
GB-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rpbmlEPTB;MUC5MlAzKG6P NUjQRoQ5W0GQR1XS
SNB75 MmPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUK3PHJGUUN3ME2xNVkvPjlibl2= MkDhV2FPT0WU
BB65-RCC M2fxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDPTWM2OD1zMUmuPVMhdk1? NVfYUYVDW0GQR1XS
NCI-N87 NEnqW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTF{MT65PEBvVQ>? MWnTRW5ITVJ?
IST-MEL1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3zZ|VCUUN3ME2xNlIvOzhibl2= MYLTRW5ITVJ?
HOP-62 NXHyTIJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NImzSFhKSzVyPUGyOk45QSCwTR?= NVjSdoRNW0GQR1XS
ACN NYX1TXA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW1TWM2OD1zNE[uO|Uhdk1? MVPTRW5ITVJ?
DMS-114 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mny2TWM2OD1zNUCuOlchdk1? M2nBWHNCVkeHUh?=
MLMA NW\SPGo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTF3OT64PEBvVQ>? NFjRO|VUSU6JRWK=
HT-144 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{CyOGlEPTB;MU[1MlQ{KG6P MW\TRW5ITVJ?
C2BBe1 NHrYPG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TKdGlEPTB;MU[3Mlc3KG6P M{LFeXNCVkeHUh?=
L-428 NGnuflRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDKO25KSzVyPUG3O{44KG6P M3vGSnNCVkeHUh?=
DU-4475 Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2SxVWlEPTB;MUi3MlY5KG6P NHjYNHRUSU6JRWK=
CP67-MEL NYrFRpN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLhUZpMUUN3ME2xPVkvOzhibl2= NYThSI9jW0GQR1XS
MEG-01 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\PVWlEPTB;MkCxMlk3KG6P NVqxclB[W0GQR1XS
IST-SL2 MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TiV2lEPTB;MkC4MlY{KG6P M1nDSHNCVkeHUh?=
ES8 M1fnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfQR3RKSzVyPUKyOU46PCCwTR?= M1fY[HNCVkeHUh?=
COLO-800 M3m2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PvfWlEPTB;MkO1MlI5KG6P Mnv3V2FPT0WU
MFH-ino NF3EcJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj4WYNKSzVyPUKzOU45PCCwTR?= M2\QSHNCVkeHUh?=
OVCAR-4 MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJ|Nz6yOEBvVQ>? MnTGV2FPT0WU
PSN1 Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYC1Ro83UUN3ME2yOFIvPzFibl2= MUfTRW5ITVJ?
EW-12 NUPsPGx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmeyTWM2OD1{NEOuNUBvVQ>? NEXVTlhUSU6JRWK=
HCC1599 NVnB[3VvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3ncHBpUUN3ME2yOlEvPDdibl2= MVPTRW5ITVJ?
SJSA-1 Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLPR2NKSzVyPUK3NU41PiCwTR?= MlnEV2FPT0WU
ST486 NU\oeFdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrwTWM2OD1{OU[uNVQhdk1? NHjxdoxUSU6JRWK=
NOMO-1 NIDo[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTNyMD6yNUBvVQ>? MlT4V2FPT0WU
MN-60 M{\C[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTNyNT6zNkBvVQ>? NI[ybWVUSU6JRWK=
HCC1187 NY\2e2pYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\O[Wp1UUN3ME2zNFcvOjVibl2= Mk\LV2FPT0WU
SW982 NGm1SWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37CU2lEPTB;M{G0Mlc2KG6P Ml;iV2FPT0WU
LB647-SCLC NGrpdWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTN{OD63NUBvVQ>? NV\HNZl7W0GQR1XS
HC-1 MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHzTWM2OD1|M{WuOUBvVQ>? MX\TRW5ITVJ?
EHEB M2Hl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTN|Nz61NkBvVQ>? Mn;CV2FPT0WU
TUR NEHOW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DQPGlEPTB;M{[zMlk2KG6P MUDTRW5ITVJ?
LU-139 M{nXVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HE[mlEPTB;M{e4MlAzKG6P NXHpdYpjW0GQR1XS
NB1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfUTIxKSzVyPUO4OE41PSCwTR?= M1L0fHNCVkeHUh?=
BB30-HNC NVKxO21ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPNTWM2OD1|OEiuN|Ihdk1? MVTTRW5ITVJ?
HAL-01 NVnjNFM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTN6OT6yOkBvVQ>? MYTTRW5ITVJ?
K5 NFOwPGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXsT3VKSzVyPUSxNU4{PyCwTR?= MXXTRW5ITVJ?
MZ2-MEL Mmj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rlSGlEPTB;NEGzMlY1KG6P M2rn[XNCVkeHUh?=
RXF393 MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTRzNj60OUBvVQ>? NF71eJhUSU6JRWK=
NCI-H1648 Ml;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTRzNz61N{BvVQ>? MUjTRW5ITVJ?
TE-12 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13WW2lEPTB;NEO0MlI3KG6P MVnTRW5ITVJ?
EoL-1- MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M176NWlEPTB;NEO3Mlk5KG6P M2XvO3NCVkeHUh?=
JAR NF3lcWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\3N2lEPTB;NEO4MlYzKG6P NFW2XopUSU6JRWK=
DSH1 M4nwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTR3OD65NUBvVQ>? MUfTRW5ITVJ?
NCI-H187 NFzqWYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXuboFoUUN3ME20OlIvQDFibl2= NHrtdohUSU6JRWK=
HCE-4 MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TKN2lEPTB;NEe3MlY3KG6P NIHlfHlUSU6JRWK=
8-MG-BA M{DBbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnaTm9KSzVyPUW4NU42OiCwTR?= MnP4V2FPT0WU
KLE MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTaVpJpUUN3ME21PFUvOiCwTR?= Ml;0V2FPT0WU
KNS-42 M3\1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HJNGlEPTB;NUi2MlgyKG6P NEPSZZhUSU6JRWK=
MSTO-211H MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTnWG9KSzVyPU[wPU44PCCwTR?= NX7JOWc4W0GQR1XS
GDM-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Lxd2lEPTB;NkG0MlA6KG6P NGD6WJBUSU6JRWK=
TE-1 NEf0VXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH72O2NKSzVyPU[0Ok4yOiCwTR?= NXfIOGpFW0GQR1XS
BT-474 Ml3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTZ2Nz6wOkBvVQ>? M371SnNCVkeHUh?=
KARPAS-45 M3XwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:2TnhKSzVyPU[0O{43KG6P M3H5UnNCVkeHUh?=
MOLT-16 MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnKSIhMUUN3ME22OFcvQTNibl2= M{XNVnNCVkeHUh?=
KURAMOCHI MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTRWJQ3UUN3ME22OVcvPTFibl2= NIrWW2pUSU6JRWK=
K-562 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHCTWM2OD14NkmuOVEhdk1? NUjiTFhnW0GQR1XS
EKVX NYTXTFA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTKcnZtUUN3ME22O|IvPzFibl2= M4KzeXNCVkeHUh?=
GAK NF3BN|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTZ5NT6zJI5O M17GNHNCVkeHUh?=
NCI-SNU-5 NGG0RlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDre|lJUUN3ME22PVAvODFibl2= MUDTRW5ITVJ?
NCI-H2126 M2TDT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnqTXprUUN3ME23NlYvQDdibl2= Mlu3V2FPT0WU
CTV-1 M3LBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XtRmlEPTB;N{S0Mlkhdk1? M3PzWXNCVkeHUh?=
SW962 NIrhfWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTd2OD60OEBvVQ>? NGDISoVUSU6JRWK=
MONO-MAC-6 NI\aOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTiTWM2OD15NU[uPVMhdk1? MnzKV2FPT0WU
NCI-H748 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDkTWM2OD15NUiuPVkhdk1? NFjO[nBUSU6JRWK=
NCI-H524 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTd6MD63N{BvVQ>? Mn;FV2FPT0WU
LS-123 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjCV495UUN3ME23PVUvPjlibl2= NWnjNpY5W0GQR1XS
NB7 M1rGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:0NlVKSzVyPUixOE4yPCCwTR?= NF;KWpdUSU6JRWK=
LS-1034 NVzrVlR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\0UHhZUUN3ME24NlgvQThibl2= MmLPV2FPT0WU
TE-5 M2fUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TtOWlEPTB;OEizMlU3KG6P NX34ZYpnW0GQR1XS
A704 NF;OeG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPjTWM2OD16OUmuNVUhdk1? NHOwfoNUSU6JRWK=
TK10 M{O4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\GXmlEPTB;OUG2MlA{KG6P Ml64V2FPT0WU
NCI-H345 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPSZYxKSzVyPUm0N{4zOiCwTR?= NUO0O2xiW0GQR1XS
CGTH-W-1 M{LVPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX2PJVEUUN3ME25OFgvOTNibl2= MXPTRW5ITVJ?
NCI-H510A MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;MU5dKSzVyPUm4OU4yOiCwTR?= NV\FT4F7W0GQR1XS
NCI-H1963 M3vnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTFwMEOyPVIh|ryP NGTMflBUSU6JRWK=
SCC-3 MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTFwMEO0NVQh|ryP M3yyZ3NCVkeHUh?=
EW-11 MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\uTWM2OD1zLkC4O|Q{KM7:TR?= M1jPVHNCVkeHUh?=
CPC-N MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjNPIhKSzVyPUGuNFg5KM7:TR?= M3\TdnNCVkeHUh?=
NCI-H1417 NVHoN3c2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4C5eWlEPTB;MT6xNlI3KM7:TR?= MmPQV2FPT0WU
DG-75 NXzpNmE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGn3em1KSzVyPUGuNVYzQDVizszN NFTRd|RUSU6JRWK=
HD-MY-Z MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH0TWM2OD1zLkG2OFE3KM7:TR?= NH25ZoZUSU6JRWK=
ATN-1 NGDLcXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFwMk[yNFkh|ryP NUPS[YhkW0GQR1XS
KM-H2 NWTsPGR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\sdGlEPTB;MT6yOlQxQCEQvF2= MVHTRW5ITVJ?
NCI-H2081 NF3i[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1frfmlEPTB;MT6yOlY{PyEQvF2= MXzTRW5ITVJ?
HL-60 NXLUSFlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTFwMk[5OVkh|ryP M2X5THNCVkeHUh?=
DB M2DT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTFwMkeyOFIh|ryP NV\xTXM5W0GQR1XS
NCI-H1522 M1;FfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\yUoM{UUN3ME2xMlI5QDh5IN88US=> NVrCXnRSW0GQR1XS
AM-38 MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13mfWlEPTB;MT6zNFczKM7:TR?= MkToV2FPT0WU
NCI-H446 M2XCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;QcZJPUUN3ME2xMlMzOTJzIN88US=> NGP3UnhUSU6JRWK=
SU-DHL-1 NGjLbGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1SxUGlEPTB;MT6zNlgxOSEQvF2= MYXTRW5ITVJ?
NH-12 MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DVcmlEPTB;MT6zOlM4PCEQvF2= NGjLfGxUSU6JRWK=
DMS-79 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:zTWM2OD1zLkO2PFY3KM7:TR?= Ml3GV2FPT0WU
NCI-H716 NV6zZ|JlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPYTWM2OD1zLkO4PVg3KM7:TR?= NE\uO4hUSU6JRWK=
ML-2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfQXVRKSzVyPUGuOFE2OjlizszN M{DjdHNCVkeHUh?=
NB10 NWnUSYhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXU[2lOUUN3ME2xMlQ3PjN{IN88US=> M4rsPHNCVkeHUh?=
ONS-76 Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTFwNUO1Olkh|ryP MVXTRW5ITVJ?
LOUCY Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS2TWM2OD1zLkW0OlU4KM7:TR?= M2TsW3NCVkeHUh?=
SCLC-21H MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7aWlJKSzVyPUGuOVg2QDJizszN MkTLV2FPT0WU
TGW NXzFdpNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTFwNkO5O|Uh|ryP NFj5cVNUSU6JRWK=
LXF-289 NWHGZY8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrVW|JOUUN3ME2xMlc{OjZ6IN88US=> NXnTSHpSW0GQR1XS
BB49-HNC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPwTWM2OD1zLkezOVg3KM7:TR?= NGfsbHFUSU6JRWK=
NCI-H747 NH;2XVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkT1TWM2OD1zLke1N|Q3KM7:TR?= MY\TRW5ITVJ?
LU-165 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1uyfGlEPTB;MT64OFk5PiEQvF2= MXXTRW5ITVJ?
OMC-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXvUZdoUUN3ME2xMlk2ODZ4IN88US=> MXfTRW5ITVJ?
RCC10RGB M1niVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PnXGlEPTB;MT65OVgyPyEQvF2= MnjIV2FPT0WU
SW684 NHTPbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrPfHVOUUN3ME2xMlk3ODl7IN88US=> M1LnOXNCVkeHUh?=
TE-8 Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLsTWM2OD1{LkC1OVU6KM7:TR?= M1LVdnNCVkeHUh?=
SK-N-DZ M3zQbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPVV2Z6UUN3ME2yMlE{Ojd2IN88US=> MUjTRW5ITVJ?
EVSA-T MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;WSIxKSzVyPUKuNVc{OTVizszN MV7TRW5ITVJ?
KASUMI-1 NGLLenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTJwMUi4NVUh|ryP NVLESWJyW0GQR1XS
NKM-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjIcHFOUUN3ME2yMlI2PDd{IN88US=> NEDOfoZUSU6JRWK=
CAL-148 MnOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJwM{O2NVQh|ryP M1XhNHNCVkeHUh?=
NCI-H64 NYXSSGRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3k[GNKSzVyPUKuN|QzOzJizszN MnGwV2FPT0WU
KNS-81-FD NYTlc3JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnXTWM2OD1{LkO2OlIh|ryP NG\YW3RUSU6JRWK=
KM12 NE\TUXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;NTWM2OD1{LkSwPFM6KM7:TR?= MVjTRW5ITVJ?
SW954 NF3w[29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\2eVhMUUN3ME2yMlQ4Pzd7IN88US=> NYXvS4V6W0GQR1XS
NCI-H1395 NGXY[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7JN5lYUUN3ME2yMlUzPjR3IN88US=> NF7JV5NUSU6JRWK=
DJM-1 M2DzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJwNkC2N{DPxE1? M1rRUnNCVkeHUh?=
COLO-668 NUPhbJpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDNTWM2OD1{LkiyOlk2KM7:TR?= MWLTRW5ITVJ?
NCI-H1436 M1;Zfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S4TWlEPTB;Mj64OVYyPSEQvF2= MUHTRW5ITVJ?
LB2241-RCC NYnMWpl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvv[4ZKSzVyPUKuPFY5OzlizszN NYLX[m9qW0GQR1XS
GT3TKB NYnkPFJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;IXGlEPTB;Mj64PVA2PSEQvF2= NF[5b29USU6JRWK=
COLO-824 MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTJwOEm3Olgh|ryP NHvmcJNUSU6JRWK=
ES1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jPN2lEPTB;Mj64PVg4QSEQvF2= NVLSfpB2W0GQR1XS
LB771-HNC M4PGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mon2TWM2OD1{LkmwPVQ3KM7:TR?= NW\ITYl{W0GQR1XS
GI-ME-N NIXGSlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHiTWM2OD1|LkCwPVA1KM7:TR?= NXzMTW1oW0GQR1XS
NALM-6 MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLKRnJKSzVyPUOuNFA6OzNizszN MmmwV2FPT0WU
LU-134-A MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTNwMEW0NlUh|ryP MWjTRW5ITVJ?
DMS-153 NH;kXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTpTWM2OD1|LkC1PFI1KM7:TR?= MnrsV2FPT0WU
MZ1-PC MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTNwMEmwO|gh|ryP M{f0SnNCVkeHUh?=
NCI-H1155 M{WyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TJNmlEPTB;Mz6xNVYyKM7:TR?= MlH2V2FPT0WU
CAS-1 NV7YeW1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7BTWM2OD1|LkGzO|A4KM7:TR?= NXfkSW9VW0GQR1XS
D-502MG NVL5TXZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTNwMUSzPUDPxE1? NX;kOJFiW0GQR1XS
NCI-H2141 NV3wO3VHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1X0dWlEPTB;Mz6xO|Q2OiEQvF2= M4rh[XNCVkeHUh?=
NB6 NF;U[4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnUem1KSzVyPUOuNVgzPTlizszN MWLTRW5ITVJ?
NCCIT NEj1fldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv2NFhVUUN3ME2zMlIyQDB7IN88US=> Ml\kV2FPT0WU
NB69 NV7UV5loT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDNTWM2OD1|LkOxPFkyKM7:TR?= M4DN[XNCVkeHUh?=
JVM-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\tT5NMUUN3ME2zMlM3PDN|IN88US=> M3LrUHNCVkeHUh?=
K052 M1i2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFuyU2FKSzVyPUOuN|c6PjhizszN NFLFXXdUSU6JRWK=
HCC2157 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlG5TWM2OD1|LkWzNlI5KM7:TR?= NGjHXXpUSU6JRWK=
KMOE-2 NUPRTZFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zEVWlEPTB;Mz61OFI1OiEQvF2= MnfhV2FPT0WU
SF268 NWDySVY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3lTWM2OD1|LkexOVU1KM7:TR?= MWHTRW5ITVJ?
CHP-126 NGXQZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnniTWM2OD1|Lke2OFU5KM7:TR?= NVTDOo5VW0GQR1XS
CP66-MEL NVyyPZVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvjVW1KSzVyPUOuO|kxQTRizszN NFrRd4xUSU6JRWK=
NCI-H69 MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon0TWM2OD12LkCxPVM3KM7:TR?= MlnnV2FPT0WU
A253 M3HhWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jHeWlEPTB;ND6wNlExOSEQvF2= MlPTV2FPT0WU
NB14 NITqZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTXPXF5UUN3ME20MlExPDd7IN88US=> MmHRV2FPT0WU
NCI-H1694 NHPwfItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPJTWM2OD12LkGzNVEzKM7:TR?= NX\4R4V[W0GQR1XS
NCI-H2196 MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjKWm5KSzVyPUSuNVcyPjlizszN M2nPR3NCVkeHUh?=
TE-9 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjpTWM2OD12LkG3OVgzKM7:TR?= MWDTRW5ITVJ?
D-283MED NVLM[HJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTRwMUi4OEDPxE1? NH:zOYNUSU6JRWK=
OCI-AML2 NFrpR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXSxS|VGUUN3ME20MlE6PDh7IN88US=> NYjjRlg{W0GQR1XS
D-263MG NYPVUZp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\6W2lEPTB;ND6yNlk3OSEQvF2= NUT4VHpZW0GQR1XS
MPP-89 M2D4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PNV2lEPTB;ND6yO|MxPCEQvF2= NHTwSplUSU6JRWK=
LAMA-84 NVPrR5FJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmK0TWM2OD12LkOwOFIyKM7:TR?= NGX2[o9USU6JRWK=
LB373-MEL-D NUm5[mVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjkdVdKSzVyPUSuN|Y4QDlizszN NV7MV3RjW0GQR1XS
UACC-257 M2XSZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjxN3J{UUN3ME20MlM6PTN2IN88US=> MXXTRW5ITVJ?
MC-CAR NGfyVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1uwemlEPTB;ND60N|k6KM7:TR?= M4fYPHNCVkeHUh?=
COLO-320-HSR MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:2T5dKSzVyPUSuOFQ1OjdizszN MYrTRW5ITVJ?
P30-OHK NWnyToh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrNTWM2OD12Lk[2OVgyKM7:TR?= M17UOnNCVkeHUh?=
UACC-812 NWTJWJVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XKU2lEPTB;ND62PVE3OSEQvF2= MkDNV2FPT0WU
CTB-1 NIrEZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{[4WGlEPTB;ND63NVU2PSEQvF2= NYXjSnRNW0GQR1XS
ALL-PO NWPHfnNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fx[2lEPTB;ND64OFA4PyEQvF2= NWTUcJI4W0GQR1XS
SK-MEL-2 NYPpcWF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIS3WnVKSzVyPUSuPFY6PTVizszN NHW5WnFUSU6JRWK=
TC-YIK M1z2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVG2c2xuUUN3ME20Mlk4QTR{IN88US=> Mn7RV2FPT0WU
NCI-H1882 Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTVwMEKwNFEh|ryP NYL3bIhNW0GQR1XS
MHH-CALL-2 NIfnZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzhbFM{UUN3ME21MlA2ODR{IN88US=> NXjLXIEyW0GQR1XS
U-87-MG MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;FZWlEPTB;NT6wPVQ3PiEQvF2= MVTTRW5ITVJ?
NCI-H1092 MoO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3I[lZmUUN3ME21MlI3PTV3IN88US=> NHfvZ4NUSU6JRWK=
TE-441-T NFXYdWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTVwMke4NkDPxE1? NYm5dIZ2W0GQR1XS
SK-MEL-1 M1\GdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTVwMkmwOFQh|ryP MoPpV2FPT0WU
EW-22 M1fTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLMTWM2OD13LkK5OFY3KM7:TR?= MnPTV2FPT0WU
MZ7-mel MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTNeWdrUUN3ME21MlQxPjlzIN88US=> MXjTRW5ITVJ?
LP-1 M1;4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rabmlEPTB;NT60NVI6OSEQvF2= Mkf6V2FPT0WU
NCI-SNU-16 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fUbWlEPTB;NT62OFA4PCEQvF2= MnL2V2FPT0WU
LU-65 M3z5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7KbHlKSzVyPUWuO|Y{PzNizszN M3;qdXNCVkeHUh?=
CW-2 NX3oXoozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoKyTWM2OD13Lki1PVU6KM7:TR?= MX7TRW5ITVJ?
WSU-NHL MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTVwOUWxO|Qh|ryP NGPSSItUSU6JRWK=
IST-MES1 MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HxS2lEPTB;NT65OVQ1OyEQvF2= Ml\0V2FPT0WU
U-266 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVf2[JlSUUN3ME21Mlk5OjB{IN88US=> M4HrTHNCVkeHUh?=
TALL-1 M3zZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPBTWM2OD14LkG0Olg5KM7:TR?= MoD4V2FPT0WU
Calu-6 NEPBeotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XJSWlEPTB;Nj6xOVMyPiEQvF2= M2HmdHNCVkeHUh?=
MMAC-SF NVvBb|NxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfGeINjUUN3ME22MlE5PTV4IN88US=> NEHUVYZUSU6JRWK=
NCI-H82 M1r0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTDblk2UUN3ME22MlIxPDh7IN88US=> NHnaZZFUSU6JRWK=
RS4-11 MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHNTWM2OD14LkK1PFk4KM7:TR?= NWPEc5p4W0GQR1XS
SNU-C2B NUjq[o01T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnsXWNKSzVyPU[uOFA6PjlizszN MljKV2FPT0WU
BOKU NH;uVXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PLNWlEPTB;Nj60O|U6PyEQvF2= MVrTRW5ITVJ?
C8166 MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknOTWM2OD14LkW1PVEzKM7:TR?= NX3UZVc6W0GQR1XS
D-247MG NIDqNXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTdwMESzOFch|ryP NGe0PIdUSU6JRWK=
EW-18 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjLTWM2OD15LkC3NlkzKM7:TR?= Mlj5V2FPT0WU
KG-1 NEmyXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTdwNkK3N|gh|ryP M{DqUnNCVkeHUh?=
REH MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrwTWM2OD15Lk[4NVA6KM7:TR?= M1vVcHNCVkeHUh?=
U-698-M NHTjOIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnISZl{UUN3ME23Mlg1OzF3IN88US=> MYrTRW5ITVJ?
KP-N-RT-BM-1 NEDmeoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLYTWM2OD15LkmzNFI6KM7:TR?= MX;TRW5ITVJ?
MS-1 NXLNWldPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUKwfmE1UUN3ME23Mlk3ODRzIN88US=> NGTTe4JUSU6JRWK=
SNU-C1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nhSWlEPTB;Nz65PFE6OiEQvF2= NVz6[FNUW0GQR1XS
SK-MM-2 NYS5[WIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLsTWM2OD16LkK2NFY2KM7:TR?= NIflc29USU6JRWK=
LAN-6 NVrycnB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRThwM{CwNFEh|ryP MoXCV2FPT0WU
NEC8 NV7SVIpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml2zTWM2OD16LkOwOlkyKM7:TR?= NEL5O5VUSU6JRWK=
NCI-H1770 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILnOHlKSzVyPUiuN|gxODJizszN MVfTRW5ITVJ?
D-336MG MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfSPI1KSzVyPUiuOFAyOTZizszN NX;2OnhZW0GQR1XS
COLO-829 MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvlPVRKSzVyPUiuOFg5PzlizszN MUPTRW5ITVJ?
LS-513 M2rYeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRThwNUm1PVkh|ryP NWqxcmxJW0GQR1XS
YT NUnGPFhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRThwNkK0Nlch|ryP MoHTV2FPT0WU
EW-24 M2O4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRThwN{[1OEDPxE1? Mn\iV2FPT0WU
IST-SL1 NV64dmlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHThSVlKSzVyPUiuPFY2PDNizszN M4[wenNCVkeHUh?=
CA46 NHG5c45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvpTWM2OD16Lkm1NFk5KM7:TR?= NYDWZ4p3W0GQR1XS
NCI-H1838 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRThwOUi2NFIh|ryP NXr1cGVJW0GQR1XS
NCI-H719 NUfXPVg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\XbYExUUN3ME25MlI2Ojd7IN88US=> NVLSVIF3W0GQR1XS
HCE-T M{Xo[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjGemxnUUN3ME25MlMxQDVzIN88US=> NYrrbXhiW0GQR1XS
A498 Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTlwM{[xNlQh|ryP M{XXRXNCVkeHUh?=
LB831-BLC NFT4W4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnW5TWM2OD17Lke2OVIyKM7:TR?= MkHzV2FPT0WU
SKM-1 M3[3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTlwOEW5OlMh|ryP MmWxV2FPT0WU
THP-1 NX:wRnk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHS1VnFKSzVyPUmuPVY6OThizszN M37ocnNCVkeHUh?=
SHP-77 MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\FTWM2OD1zMD60NFch|ryP MVTTRW5ITVJ?
EW-3 NVv2TFlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf3TWM2OD1zMD62Nlg6KM7:TR?= MUjTRW5ITVJ?
KY821 M{TQUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS0SZpKSzVyPUGwMlc3OyEQvF2= MXLTRW5ITVJ?
NCI-SNU-1 NYXpfotjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7HbZZ[UUN3ME2xNU4xOjF5IN88US=> NUTwbnpLW0GQR1XS
HCC2218 NUH2RopWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnpRYRxUUN3ME2xNU4{QTh4IN88US=> Mlj4V2FPT0WU
IM-9 NIHvNmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTFzLkWxNFYh|ryP MmS3V2FPT0WU
NCI-H889 M1fqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzuTWM2OD1zMT61N|E{KM7:TR?= M2\nNHNCVkeHUh?=
HDLM-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUmy[ZV[UUN3ME2xNk41OTV7IN88US=> MUHTRW5ITVJ?
LB2518-MEL NWnVdW1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTF{Lk[4NVUh|ryP MoH6V2FPT0WU
NCI-H23 NGXGcndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTF|LkK0NlUh|ryP MXjTRW5ITVJ?
NB17 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF|LkS1O|kh|ryP NF3FV4lUSU6JRWK=
NCI-H322M M4rITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHaNWFFUUN3ME2xOE41ODZ6IN88US=> NFzvXm5USU6JRWK=
SUP-T1 MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPOVGRKSzVyPUG0MlQyOyEQvF2= NVvQc3RHW0GQR1XS
ES3 NVf2doNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTF3LkC3NFMh|ryP M2r0SXNCVkeHUh?=
ES5 MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfZTmpKSzVyPUG1MlA4QDdizszN NW\oZoxXW0GQR1XS
NCI-H1650 NEPIc5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTF3LkS5O|kh|ryP M2nvWHNCVkeHUh?=
NCI-H226 MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjLNm1[UUN3ME2xOU45PzZ6IN88US=> M3T4PHNCVkeHUh?=
COR-L88 NV\idXF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTF4LkOxOEDPxE1? NXfxSGxFW0GQR1XS
SCC-15 M3HUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWX2ZXY3UUN3ME2xOk4{QDZ7IN88US=> MWjTRW5ITVJ?
GOTO NF\NbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rEe2lEPTB;MU[uOFc6OyEQvF2= M3nIc3NCVkeHUh?=
SIMA NEfiXI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrQTWM2OD1zNj60PFAzKM7:TR?= M1jYSXNCVkeHUh?=
NCI-H1299 NIG1cphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPDWplKSzVyPUG3MlE2QTFizszN MoDhV2FPT0WU
NCI-H1581 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;RTWM2OD1zNz60NlE6KM7:TR?= MXLTRW5ITVJ?
MHH-NB-11 NUH1TWlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvSNIFSUUN3ME2xO{46Pjh|IN88US=> M{XofHNCVkeHUh?=
MFM-223 NVSxOXdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTF6LkC1N|gh|ryP M3G1NHNCVkeHUh?=
ES7 MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTITWM2OD1zOD61OFMyKM7:TR?= NFH3d4FUSU6JRWK=
JVM-3 M125fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXuNpZTUUN3ME2xPE44OTdizszN MWLTRW5ITVJ?
RL NHz6fIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJyLkO4PEDPxE1? NIm0S5dUSU6JRWK=
EC-GI-10 M1r2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvXc|RWUUN3ME2yNU4zODRzIN88US=> MkTZV2FPT0WU
LNCaP-Clone-FGC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;iOIxsUUN3ME2yNU43PzZ6IN88US=> M1S0eXNCVkeHUh?=
IMR-5 NF7KZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTnfWRKSzVyPUKxMlg1QTRizszN NIiz[HhUSU6JRWK=
KP-N-YS M3OzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJzLki3OUDPxE1? NXX6cHRlW0GQR1XS
Mo-T NG\ncG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnryTWM2OD1{Mj6yNVg2KM7:TR?= NVTUSYFWW0GQR1XS
NCI-H128 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJ|LkW4OVMh|ryP NV7mRmFGW0GQR1XS
RH-1 MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvBTI41UUN3ME2yN{44QDZ4IN88US=> MWXTRW5ITVJ?
NCI-H2171 NH;zWmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DkXWlEPTB;MkSuNlQ5PSEQvF2= NYT6eW9tW0GQR1XS
RPMI-8866 NVL5VXoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPrS2tzUUN3ME2yOk44PDJizszN MYfTRW5ITVJ?
SK-N-FI NF;UUnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoGzTWM2OD1{Nz6zPFEyKM7:TR?= MWfTRW5ITVJ?
LOXIMVI NFyzOoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjsfJhKSzVyPUK3MlgxPTFizszN MYjTRW5ITVJ?
P31-FUJ M321TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37hOWlEPTB;M{GuOVM4PCEQvF2= MVXTRW5ITVJ?
KMS-12-PE M1\3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3q5NWlEPTB;NEmuOVMxOiEQvF2= MXPTRW5ITVJ?

... Click to View More Cell Line Experimental Data

体内研究 在体内,Rapamycin 处理,特定阻断mTOR下游靶点,如p70S6K磷酸化和激活,和PHAS-1/4E-BP1导致的eIF4E抑制释放, 完全阻断跖肌重量和纤维尺寸的肥厚增高。[3] 短期Rapamycin处理,即使按最低剂量0.16 mg/kg处理, 强抑制p70S6K活性, 与提高的肿瘤细胞死亡和Eker肾脏肿瘤坏死相关。[4] Rapamycin作用于CT-26移植瘤模型,通过降低VEGF产量,及阻断VEGF诱导的内皮细胞信号,而抑制转移性肿瘤生长和血管新生。[5] Rapamycin每天按4 mg/kg剂量处理C6移植瘤,显著降低肿瘤生长,和肿瘤血管通透性。[7]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

mTOR激酶免疫印迹法测定:

HEK293细胞按每孔2-2.5×105个细胞接种在12孔板上,DMEM培养基上血清饥饿处理24小时。使用浓度不断增加的Rapamycin(0.05-50 nM)在 37oC下处理细胞15分钟。加入血清,终浓度为20%,在37oC下处理30分钟。细胞溶解,使用SDS-PAGE分离细胞裂解液。再溶解的蛋白转移到聚偏(二)氟乙烯膜上,使用抗p70 S6激酶Thr-389的磷酸化的一抗进行免疫印迹。使用ImageQuant 和KaleidaGraph分析数据。
细胞实验:

[6]

+ 展开
  • Cell lines: U87-MG, T98G, 和 U373-MG
  • Concentrations: 溶于DMSO,终浓度为~25 μM
  • Incubation Time: 72 小时
  • Method:

    使用不同浓度Rapamycin处理细胞72小时。为了测量细胞活力,通过胰蛋白酶化收集细胞,使用台酚蓝染色,计数每孔的存活细胞数。为了测定细胞周期, 使细胞胰蛋白酶化,与70%乙醇混合, 使用碘化丙啶染色。使用FACScan流式细胞仪和CellQuest软件分析样本DNA含量。为了测定凋亡, 细胞染色,通过末端脱氧核苷酸转移酶调节的dUTP缺口末端标记法(TUNEL)技术,使用一个ApopTag凋亡检测试剂盒对细胞进行染色。为了测定酸性囊泡细胞器(AVO)的进展,使用吖啶橙(1 μg/mL)对细胞进行染色15分钟,使用荧光显微镜检测。为了量化AVOs的进展,使用吖啶橙(1 μg/mL) 对细胞进行染色15分钟, 然后使用胰蛋白酶-EDTA使其从实验板上移除,最后使用FACScan流式细胞仪和CellQuest 软件分析。为了分析自噬过程,细胞和0.05 mM丹(磺)酰戊二胺(MDC)在37oC下温育10分钟,然后在荧光显微镜下观察。


    (Only for Reference)
动物实验:

[7]

+ 展开
  • Animal Models: 皮下接种表达VEGF-A的C6大鼠胶质瘤细胞的无胸腺Nu/Nu小鼠
  • Formulation: 溶于溶剂溶液(0.2% 羧甲基纤维素和0.25% Tween-80,溶于无菌水)
  • Dosages: ~4 mg/kg/day
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 914.18
化学式

C51H79NO13

CAS号 53123-88-9
稳定性 powder
in solvent
别名 AY 22989,NSC-2260804

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

相关mTOR产品

Tags: 购买Rapamycin (Sirolimus) | Rapamycin (Sirolimus)供应商 | 采购Rapamycin (Sirolimus) | Rapamycin (Sirolimus)价格 | Rapamycin (Sirolimus)生产 | 订购Rapamycin (Sirolimus) | Rapamycin (Sirolimus)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID